NICE (UK) announce criteria for access to Daklinza, Harvoni, Viekirax and Exviera
Cinnamon Girl said
Oct 16, 2015
Very good news for Hep C patients in the UK with Gen 1 and 4, and some with Gen 3!
The National Institute of Clinical Excellence (NICE) have announced which of the new treatments would be made available by the NHS to people living with hepatitis C. This NICE decision is concerned with widening access beyond patients who were given access to new treatments earlier this year under the Early Access Scheme for those with decompensated cirrhosis.
The new treatments under consideration are:
Harvoni, a combination of two drugs, ledipasvir and sofosbuvir. It is produced by Gilead
Daklinza, a combination of two drugs, daclatasvir and sofosbuvir. Daclatasvir produced by Bristol Myers Squibb and sofosbuvir by Gilead.
Viekirax, is a combination of four drugs, ombitasvir, paritaprevir, ritonavir and Exviera (dasabuvir). They are produced by AbbVie.
All those with genotypes 1 and 4, should now be able to access the new non-interferon based treatments with shorter treatment times and less severe side effects.
Some people living with genotype 3, can access Daklinza. None of the treatments looked at by NICE at this stage are for genotype 2, there are trials taking place for new treatments for this genotype.
Full details of treatment criteria, by genotype...
Very good news for Hep C patients in the UK with Gen 1 and 4, and some with Gen 3!
The National Institute of Clinical Excellence (NICE) have announced which of the new treatments would be made available by the NHS to people living with hepatitis C. This NICE decision is concerned with widening access beyond patients who were given access to new treatments earlier this year under the Early Access Scheme for those with decompensated cirrhosis.
The new treatments under consideration are:
Harvoni, a combination of two drugs, ledipasvir and sofosbuvir. It is produced by Gilead
Daklinza, a combination of two drugs, daclatasvir and sofosbuvir. Daclatasvir produced by Bristol Myers Squibb and sofosbuvir by Gilead.
Viekirax, is a combination of four drugs, ombitasvir, paritaprevir, ritonavir and Exviera (dasabuvir). They are produced by AbbVie.
All those with genotypes 1 and 4, should now be able to access the new non-interferon based treatments with shorter treatment times and less severe side effects.
Some people living with genotype 3, can access Daklinza. None of the treatments looked at by NICE at this stage are for genotype 2, there are trials taking place for new treatments for this genotype.
Full details of treatment criteria, by genotype...
http://www.hepctrust.org.uk/news/oct-2015/nice-announce-criteria-access-daklinza-harvoni-viekirax-and-exviera